MedTrace Logo

Ezetimibe and Atorvastatin Therapy on TCFA

NCT02588235 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-10-27

No results posted yet for this study

Summary

After successful coronary angiography and OCT examination, patients with TCFAs in non-culprit, mild-to-moderate stenotic lesions will be enrolled. Then, they will be randomly assigned in a 1:1 ratio to receive either atorvastatin (20 mg/day) alone or atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）by envelope method. Angiographic and OCT follow-up will be scheduled for the target vessel after 12 months.

Conditions

Interventions

DRUG

Ezetimibe and Atorvastatin

atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）

DRUG

Atorvastatin

atorvastatin (20 mg/day）

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Yan Li, M.D., Ph.D. · Xijing Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02588235 on ClinicalTrials.gov